MIRA Pharmaceuticals Acquires SKNY Pharmaceuticals, Boosting Pipeline

MIRA Pharmaceuticals has completed its acquisition of SKNY Pharmaceuticals, enhancing its financial standing with an addition of $5 million in marketable securities. This strategic move broadens MIRA's development pipeline, notably introducing SKNY-1, a drug candidate targeting obesity and nicotine addiction.

SKNY-1 is an innovative oral therapy intended to improve metabolic functions and reduce cravings without psychiatric side effects. Preclinical trials report a significant reduction in body weight and reversal of nicotine cravings, heralding its dual potential in therapeutic applications.

In parallel, MIRA continues advancing Ketamir-2, a next-generation ketamine analog displaying promising results in neuropathic pain management with potential applications in depression and PTSD. Additionally, MIRA-55 offers a novel cannabis-derived solution for inflammatory pain, aiming to provide relief without the risk of opioid addiction.

MIRA's strategic focus targets major healthcare markets, addressing substantial unmet needs in obesity, addiction, and pain management through its diverse program offerings.